Lava Therapeutics, which is developing cancer treatments based on research at Amsterdam University Medical Centers, floated in a $101m offering.

Lava Therapeutics, a Netherlands-based immuno-oncology therapy developer that counts pharmaceutical companies Biox Biosciences, Novo, Sanofi and Merck & Co among its shareholders, has raised approximately $101m in a US initial public offering. The offering consisted of 6.7 million shares priced at $15.00 each, in the middle of the $14 to $16 range set by the…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.